Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
IMNM Stock Chart & Stats
$22.41
-$0.28(-2.60%)
At close: 4:00 PM EST
$22.41
-$0.28(-2.60%)
Day’s Range― - ―
52-Week Range$5.15 - $25.30
Previous CloseN/A
Volume79.27K
Average Volume (3M)2.73M
Market Cap
$2.47B
Enterprise Value$761.36M
Total Cash (Recent Filing)$272.64M
Total Debt (Recent Filing)$4.01M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Mar 19, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding110,335,270
10 Day Avg. Volume2,478,855
30 Day Avg. Volume2,728,257
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)3.44
Price to Sales (P/S)68.88
P/FCF Ratio-5.28
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue78.66
Enterprise Value/Gross Profit-18.92
Enterprise Value/Ebitda-3.78
Forecast
1Y Price Target
$33.00Price Target Upside47.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.57
Revenue Forecast (FY)$10.40M
Bulls Say, Bears Say
Bulls Say
Clinical Results And Regulatory PathPhase 3 results for varegacestat support a planned New Drug Application filing and position the therapy as a potential best-in-class systemic treatment for desmoid tumors.
Financing And Cash RunwayA $400 million equity financing provides capital to support a potential commercial launch of varegacestat and extends the company's financial runway into 2028.
Pipeline MilestonesA pipeline with upcoming clinical milestones, including Phase 1 ROR1-ADC IM-1021 data in lymphomas and planned Phase 1 initiation of IM-3050 in 2026, creates multiple value-driving catalysts.
Bears Say
Commercial Execution RiskThe shift toward commercial launch performance concentrates risk on pricing, distribution across targeted centers, and patient adoption, which could depress valuation if execution falls short.
Competitive LandscapePresence of approved gamma secretase inhibitors and other competing therapies creates headwinds that could limit varegacestat uptake and pressure market share expectations.
Market Sentiment And Short InterestElevated short interest exceeding 20% of the float signals pronounced market skepticism that could amplify downside pressure on the share price.
Immunome News
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $5.15 and its highest was $25.30 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $2.47B.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is Mar 19, 2026 which is in 59 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Nov 06, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.566 by -$0.084.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.58.
How many shares outstanding does Immunome have?
Immunome has 110,335,270 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.566. Following the earnings report the stock price went down -1.677%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunome Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (47.26% Upside)
$33.00 (47.26% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 223.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 10.0%
Last 30 Days ▲ 39.2%
Last 30 Days ▲ 39.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
127.28%
12-Months-Change
Fundamentals
Return on Equity
-93.04%
Trailing 12-Months
Asset Growth
16.54%
Trailing 12-Months
Company Description
Immunome
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
IMNM Stock 12 Month Forecast
Average Price Target
$33.00
▲(47.26% Upside)
Technical Analysis
Ownership Overview
4.91% Insiders
21.74% Mutual Funds
0.04% Other Institutional Investors
62.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---